Axumin PET/CT Scans in Men with Suspected Recurrent Prostate Cancer May Change Treatment Plans

Axumin PET/CT Scans in Men with Suspected Recurrent Prostate Cancer May Change Treatment Plans
More than six out of 10 men whose doctors suspected their prostate cancer had returned due to rising prostate specific antigen (PSA) levels saw their treatment plans revised after being submitted to PET/CT imaging with Axumin (18F-fluciclovine). That's according to the Phase 3 FALCON trial (NCT02578940), whose findings were recently presented at the 2017 American Society for Radiology Oncology (ASTRO) Annual Meeting in San Diego. The oral presentation, “Impact of 18F-fluciclovine PET/CT on clinical management of patients with recurrent prostate cancer: results from the Phase III FALCON trial,” reported that early and accurate localization of metastasis facilitates treatment, as the tumors are smaller in size and respond better to localized therapy. Axumin, a 18F-fluciclovine injection, is a molecular agent used in positron emission tomography (PET) imaging in men with suspected recurrent prostate cancer. The suspicion is supported by high levels of PSA in the blood, following prior treatment. The U.S. Food and Drug Administration (FDA) has approved this injection for use in PET imaging, but not for treatment planning in men with biochemically recurrent prostate cancer. With this in mind, researchers aimed to assess the imp
Subscribe or to access all post and page content.